Inclusion Criteria:  Women and men aged 18 and over. Requiring treatment for COVID 19 and whose clinical status corresponds to a score equal to or greater than 5 on the WHO Clinical Progression Scale. For the prospective study, able to give informed consent. Not presenting an exclusion criterion  Exclusion Criteria:  Pregnancy Patients with pre-existing terminal condition with life expectancy < 6 months Patient with clinically frailty according to a score of the clinical frailty scale equal or superior to 7 Patients with pre-existing severe lung disease requiring home oxygen therapy. Patients with pre-existing severe hepatic cirrhosis (Grade C according to the Child-Pugh classification) Patients with pre-existing kidney failure (GFR strictly less than 15ml/min/1.73m2 according The KDIGO classification) or requiring renal replacement therapy. Patients with pre-existing angle-closure glaucoma Patient with symptomatic prostatic hypertrophy or bladder neck obstruction Patient with history of seizure disorder Patient with history of adverse reaction to antihistamines or to Cyproheptadine Patients taking routinely SSRI or monoamine oxidase inhibitor therapy. Patients presenting severe hepatic cytolysis with ALP >5 ULN at the time of study inclusion.